Patient Support Hotline

Call (844) 244-1309

ZERO360 is a free, comprehensive patient support service to help patients and their families navigate insurance and financial obstacles to cover treatment and other critical needs associated with cancer.


Subscribe to our E-Newsletter

Stay up-to-date on the latest news about prostate cancer. Join our distribution list to receive periodic email updates and our monthly e-newsletter.

  • Patient Support (844) 244-1309
  • Search
  • e-News Signup Enews Signup
  • Run/Walk
  • Donate

- test

Prostate Cancer Impact Alliance Seeks to Improve Patient Outcomes through Collaboration

The Prostate Cancer Impact Alliance (PCIA) has brought together a formidable and diverse group of researchers, patient advocacy groups, physicians... Read More

New Website Educates Prostate Cancer Community about Chemotherapy

Prostate cancer advocacy organizations ZERO, Us TOO International and Prostate Conditions Education Council announce the launch of an educational website... Read More

Prostate Cancer Treatments

Researchers present new findings on a Korean FDA-approved robotic system, safety of testosterone therapy after prostate cancer and active surveillance... Read More

AUA Releases Updates to Clinical Guideline on Castration-Resistant Prostate Cancer

The American Urological Association (AUA), a leading global urology association, announced updates to its Castration-Resistant Prostate Cancer (CRPC) clinical guideline,... Read More

AUA Responds to USPSTF Final Recommendations on Screening for Prostate Cancer

The AUA commends the USPSTF for its decision to maintain its upgraded recommendations for prostate cancer screening in men ages... Read More

New Studies Demonstrate Impact of BRCA, DNA Repair Gene Mutations in Prostate Cancer

Data being presented at the 112th Annual Scientific Meeting of the American Urological Association (AUA) shows new facts related to... Read More

AUA, ASTRO and SUO Release New Clinical Guideline on Standard of Care for Men with Localized Prostate Cancer

Prostate cancer is the second most common cancer in men in the United States, and is why the American Urological... Read More

Oncotype DX® Predicts 10-​Year Risk of Developing Metastatic Prostate Cancer in Low- and Intermediate-​Risk Patients

Genomic Health, Inc. today announced the presentation of new results from a large multi-center validation study, which confirmed that the... Read More